Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bilgin, Hülya
NCT05068765: The Effect of the Psychoeducation Program on the Subjective Well-being of Caregivers	Enrolling by invitation	N/A	72	RoW	Communication skills psychoeducation, General psychoeducation	ŞİRİN HARKİN	Schizophrenia, Caregiver, Psychoeducation, Communication Skills, Well-being	10/22	12/22
NCT06311825: The Effect of Horticultural Therapy on Loneliness and Life Satisfaction in Elderly Adults Living in Nursing Home	Not yet recruiting	N/A	54	RoW	Horticultural Therapy	Istanbul University - Cerrahpasa (IUC)	Horticultural Therapy, Loneliness, Satisfaction, Personal, Aging	07/24	10/24
NCT06457178: Investigation of the Effect of Acceptance and Commitment Therapy-Based Intervention in Oncology Patients	Not yet recruiting	N/A	75	NA	Acceptance and Commitment Therapy-Based Intervention for Oncology Patients, Psychoeducation for Oncology Patients	Istanbul University - Cerrahpasa (IUC)	Acceptance and Commitment Therapy	04/25	12/25
Drobotenko, Valentyna
ENSURE-2, NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis, Relapsing-Remitting	10/24	10/32
Cinar, Bilge Piri
ENSURE-2, NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis, Relapsing-Remitting	10/24	10/32
Ismail, Azza
ENSURE-2, NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis, Relapsing-Remitting	10/24	10/32